Mylan's ANDA Raises Sankyo's Blood Pressure

Law360, New York (August 2, 2006, 12:00 AM EDT) -- Mylan Pharmaceuticals Inc. must tackle a federal patent infringement suit filed by a Japanese company trying to quell Mylan’s efforts to market a generic version of anti-hypertension drug Benicar.

The lawsuit, filed in New Jersey, accuses Mylan of infringing on Daiichi Sankyo Co. Ltd.’s U.S. patent covering olmesartan medoxomil—Benicar’s active ingredient. The patent at issue is valid until 2016, according to Daiichi Sankyo.

The plaintiffs in the suit are Sankyo Company Ltd. and Daiichi Sankyo Inc.—subsidiaries of Daiichi Sankyo Co. Ltd.—based in Tokyo and New Jersey,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.